AIM ImmunoTech (AIM) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $0.17, +6.25% vs the prior close of $0.16.
- Volume 1.02M shares, 0.2x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
AIM jumps 6.3% to $0.17. Closed at $0.17, +6.25% vs the prior close of $0.16. Day range $0.16–$0.18, opened at $0.16.
AIM daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — AIM jumps 6.3% to $0.17
- Closed at $0.17, +6.25% vs the prior close of $0.16. Day range $0.16–$0.18, opened at $0.16.
- Volume was 1.02M shares, 0.2x its 50-day average of 5.78M — lighter than usual.
- Price is -22.4% vs its 50-day average ($0.22) and -68.8% vs its 200-day average ($0.55).
- 52-week range $0.16–$2.79; today's close sits at 0% of that range, 93.9% below the 52-week high.
Oct 14, 2026 — AIM slides 5.9% to $0.16, a 52-week low, 7 down days in a row
- Closed at $0.16, -5.88% vs the prior close of $0.17. Day range $0.16–$0.17, opened at $0.17.
- Volume was 559.00K shares, 0.1x its 50-day average of 5.79M — lighter than usual.
- Price is -27.7% vs its 50-day average ($0.22) and -71.0% vs its 200-day average ($0.55).
- 52-week range $0.16–$2.79; today's close sits at 0% of that range, 94.3% below the 52-week high.
- That makes 7 straight losses.
Oct 13, 2026 — AIM slides 5.6% to $0.17, 6 down days in a row
- Closed at $0.17, -5.56% vs the prior close of $0.18. Day range $0.17–$0.18, opened at $0.18.
- Volume was 611.00K shares, 0.1x its 50-day average of 5.82M — lighter than usual.
- Price is -23.8% vs its 50-day average ($0.22) and -69.4% vs its 200-day average ($0.56).
- 52-week range $0.17–$2.79; today's close sits at 0% of that range, 93.9% below the 52-week high.
- That makes 6 straight losses.
Oct 12, 2026 — AIM ends flat (+0.0%) to $0.18, 5 down days in a row
- Closed at $0.18, +0.00% vs the prior close of $0.18. Day range $0.18–$0.18, opened at $0.18.
- Volume was 482.80K shares, 0.1x its 50-day average of 5.88M — lighter than usual.
- Price is -20.0% vs its 50-day average ($0.22) and -68.0% vs its 200-day average ($0.56).
- 52-week range $0.17–$2.79; today's close sits at 0% of that range, 93.6% below the 52-week high.
- That makes 5 straight losses.
Oct 9, 2026 — AIM ends flat (+0.0%) to $0.18, 4 down days in a row
- Closed at $0.18, +0.00% vs the prior close of $0.18. Day range $0.18–$0.18, opened at $0.18.
- Volume was 416.00K shares, 0.1x its 50-day average of 5.88M — lighter than usual.
- Price is -20.5% vs its 50-day average ($0.23) and -68.3% vs its 200-day average ($0.57).
- 52-week range $0.17–$2.79; today's close sits at 0% of that range, 93.6% below the 52-week high.
- That makes 4 straight losses.
Oct 8, 2026 — AIM ends flat (+0.0%) to $0.18, 3 down days in a row
- Closed at $0.18, +0.00% vs the prior close of $0.18. Day range $0.18–$0.19, opened at $0.18.
- Volume was 483.80K shares, 0.1x its 50-day average of 5.88M — lighter than usual.
- Price is -20.9% vs its 50-day average ($0.23) and -68.6% vs its 200-day average ($0.57).
- 52-week range $0.17–$2.79; today's close sits at 0% of that range, 93.6% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — AIM ends flat (+0.0%) to $0.18
- Closed at $0.18, +0.00% vs the prior close of $0.18. Day range $0.18–$0.19, opened at $0.18.
- Volume was 547.50K shares, 0.1x its 50-day average of 5.88M — lighter than usual.
- Price is -21.3% vs its 50-day average ($0.23) and -68.9% vs its 200-day average ($0.58).
- 52-week range $0.17–$2.79; today's close sits at 0% of that range, 93.6% below the 52-week high.
Oct 6, 2026 — AIM slides 5.3% to $0.18
- Closed at $0.18, -5.26% vs the prior close of $0.19. Day range $0.18–$0.19, opened at $0.19.
- Volume was 672.50K shares, 0.1x its 50-day average of 5.87M — lighter than usual.
- Price is -21.7% vs its 50-day average ($0.23) and -69.2% vs its 200-day average ($0.58).
- 52-week range $0.17–$2.79; today's close sits at 0% of that range, 93.6% below the 52-week high.
Oct 5, 2026 — AIM jumps 5.6% to $0.19
- Closed at $0.19, +5.56% vs the prior close of $0.18. Day range $0.18–$0.19, opened at $0.19.
- Volume was 1.13M shares, 0.2x its 50-day average of 5.85M — lighter than usual.
- Price is -17.9% vs its 50-day average ($0.23) and -67.8% vs its 200-day average ($0.59).
- 52-week range $0.17–$2.79; today's close sits at 1% of that range, 93.2% below the 52-week high.
Oct 2, 2026 — AIM slides 5.3% to $0.18
- Closed at $0.18, -5.26% vs the prior close of $0.19. Day range $0.18–$0.19, opened at $0.19.
- Volume was 1.33M shares, 0.2x its 50-day average of 5.84M — lighter than usual.
- Price is -22.6% vs its 50-day average ($0.23) and -69.8% vs its 200-day average ($0.60).
- 52-week range $0.17–$2.79; today's close sits at 0% of that range, 93.6% below the 52-week high.
AIM latest news & SEC filings
Every SEC filing by or about AIM in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 30, 2026 · Form ARS — Annual report to shareholders
Annual report to shareholders
Sep 30, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Equels Thomas K bought 24,000 shares at $0.21 (≈$4.99K) on Sep 17, 2026; now holds 126,822
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Equels Thomas K bought 11,000 shares at $0.21 (≈$2.31K) on Sep 16, 2026; now holds 102,822
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Equels Thomas K bought 22,000 shares at $0.22 (≈$4.86K) on Sep 15, 2026; now holds 91,822
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Equels Thomas K bought 5,900 shares at $0.22 (≈$1.30K) on Sep 14, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
Sep 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
Sep 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 1.02 — Ended a material agreement.
- Item 3.02 — Sold unregistered shares.
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 7, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $26.00K (prior year $25.00K) (+4.0% vs Jun 30, 2025)
- Net income: -$3.79M (prior year -$2.79M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.43 (prior year -$3.68) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 5.08 — Set shareholder nomination dates.
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.02 — Ended a material agreement.
Jul 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade AIM
- Last results release: Aug 10, 2026 (8-K Item 2.02). Previous ones: May 19, 2026, Apr 16, 2020, Oct 7, 2019. Based on that rhythm, the next report is likely around Nov 9, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.98% (largest 6.3%). That is a volatile stock.
- Liquidity: about 1.20M shares (≈$203.57K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.17 vs a range of $0.16–$2.79 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1031:1000 on Feb 10, 2026, 1:100 on Jun 12, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 0 sales; latest: Thomas K Equels bought 24,000 shares on Sep 17, 2026.
- Latest filings: 8-K Sep 14, 2026; 8-K Sep 10, 2026; 8-K Sep 4, 2026.
- Share count: 30.44M shares outstanding (Aug 7, 2026), +1023.9% vs a year earlier — notable dilution.
- Listing: NYSE · industry: Biological Products, (No Diagnostic Substances).
AIM market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 0.16 | 0.18 | 0.16 | 0.17 | 1.02M |
| Oct 14, 2026 | 0.17 | 0.17 | 0.16 | 0.16 | 559.00K |
| Oct 13, 2026 | 0.18 | 0.18 | 0.17 | 0.17 | 611.00K |
| Oct 12, 2026 | 0.18 | 0.18 | 0.18 | 0.18 | 482.80K |
| Oct 9, 2026 | 0.18 | 0.18 | 0.18 | 0.18 | 416.00K |
| Oct 8, 2026 | 0.18 | 0.19 | 0.18 | 0.18 | 483.80K |
| Oct 7, 2026 | 0.18 | 0.19 | 0.18 | 0.18 | 547.50K |
| Oct 6, 2026 | 0.19 | 0.19 | 0.18 | 0.18 | 672.50K |
| Oct 5, 2026 | 0.19 | 0.19 | 0.18 | 0.19 | 1.13M |
| Oct 2, 2026 | 0.19 | 0.19 | 0.18 | 0.18 | 1.33M |
| Oct 1, 2026 | 0.18 | 0.19 | 0.18 | 0.19 | 848.10K |
| Sep 30, 2026 | 0.18 | 0.18 | 0.17 | 0.18 | 984.40K |
| Sep 29, 2026 | 0.18 | 0.18 | 0.17 | 0.17 | 2.63M |
| Sep 28, 2026 | 0.19 | 0.19 | 0.18 | 0.18 | 1.34M |
| Sep 25, 2026 | 0.20 | 0.20 | 0.19 | 0.19 | 1.92M |
| Sep 24, 2026 | 0.20 | 0.21 | 0.20 | 0.20 | 846.10K |
| Sep 23, 2026 | 0.21 | 0.21 | 0.20 | 0.21 | 1.44M |
| Sep 22, 2026 | 0.21 | 0.22 | 0.21 | 0.22 | 3.40M |
| Sep 21, 2026 | 0.21 | 0.21 | 0.20 | 0.21 | 1.49M |
| Sep 18, 2026 | 0.22 | 0.22 | 0.20 | 0.21 | 1.80M |
About AIM ImmunoTech
AIM ImmunoTech (AIM) is listed on the NYSE and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in OCALA, FL. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 946644.
AIM board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| David I. Chemerow | Director | Mar 16, 2026 |
| Thomas K Equels | CEO & President | Sep 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Thomas K Equels | CEO & President | Sep 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 17, 2026 | Thomas K Equels | Buy | 24,000 | $0.21 |
| Sep 16, 2026 | Thomas K Equels | Buy | 11,000 | $0.21 |
| Sep 15, 2026 | Thomas K Equels | Buy | 22,000 | $0.22 |
| Sep 14, 2026 | Thomas K Equels | Buy | 5,900 | $0.22 |
AIM financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $88.00K | $-13.96M | -8.62 | $-10.96M |
| Dec 31, 2024 | $170.00K | $-17.32M | -30.92 | $-14.89M |
| Dec 31, 2023 | $202.00K | $-28.96M | -0.60 | $-21.27M |
| Dec 31, 2022 | $141.00K | $-19.45M | -0.40 | $-16.11M |
| Dec 31, 2021 | $135.00K | $-19.13M | — | $-13.96M |
Latest balance sheet: total assets $12.73M, total liabilities $4.99M, cash $9.90M (as of Jun 30, 2026).
AIM earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 10, 2026 | 8-K Item 2.02 (results) | $0.26 |
| May 19, 2026 | 8-K Item 2.02 (results) | $0.41 |
| Apr 16, 2020 | 8-K Item 2.02 (results) | — |
| Oct 7, 2019 | 8-K Item 2.02 (results) | — |
| Aug 15, 2017 | 8-K Item 2.02 (results) | — |
| Apr 3, 2017 | 8-K Item 2.02 (results) | — |
| Nov 15, 2016 | 8-K Item 2.02 (results) | — |
| Aug 15, 2016 | 8-K Item 2.02 (results) | — |
| May 16, 2016 | 8-K Item 2.02 (results) | — |
| Mar 30, 2016 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on AIM
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.